The company is currently evaluating AP1189 in 2 Phase 2a clinical proof of concept (POC) trials in rheumatoid arthritis (RA), and in idiopathic membranous nephropathy (iMN, a form of nephrotic syndrome), both of which are expected to readout by year-end. SynAct recently completed a P2a POC trial in COVID-19 infected patients to speed the time to respiratory recovery and prevent severe respiratory insufficiency and the results were encouraging for further development.